# Wen‐Zhao Zhong

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/wen-zhao-zhong/

## Facts

| Field | Value |
| --- | --- |
| Citations | 12,748 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 58 |
| i10-index | 167 |
| Last Known Institution | Guangdong Academy of Medical Sciences |
| OpenAlex ID | https://openalex.org/A5082411167 |
| ORCID iD | 0000-0002-8917-8635 |
| Works | 503 |

## Researcher papers

- [Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma](https://scholariq.org/papers/potential-predictive-value-of-i-tp53-i-and-i-kras-i-mutation-status-for-response/)
- [Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study](https://scholariq.org/papers/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii/)
- [EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer](https://scholariq.org/papers/egfr-mutation-correlates-with-uninflamed-phenotype-and-weak-immunogenicity/)
- [Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-in-resected-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy](https://scholariq.org/papers/unique-genetic-profiles-from-cerebrospinal-fluid-cell-free-dna-in-leptomeningeal/)
- [Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study](https://scholariq.org/papers/erlotinib-versus-gemcitabine-plus-cisplatin-as-neoadjuvant-treatment-of-stage/)
- [Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma](https://scholariq.org/papers/specific-tp53-subtype-as-biomarker-for-immune-checkpoint-inhibitors-in-lung/)
- [Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma](https://scholariq.org/papers/single-cell-transcriptome-analysis-revealed-a-suppressive-tumor-immune/)
- [Relative Abundance of <i>EGFR</i> Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/relative-abundance-of-i-egfr-i-mutations-predicts-benefit-from-gefitinib/)
- [Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study](https://scholariq.org/papers/bevacizumab-plus-erlotinib-in-chinese-patients-with-untreated-egfr-mutated/)
- [Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer](https://scholariq.org/papers/expression-of-egfr-mutant-proteins-and-genomic-evolution-in-egfr-mutant/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Guangdong Academy of Medical Sciences](https://scholariq.org/institutions/guangdong-academy-of-medical-sciences/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.